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Abstract
Metformin (Met) is a biguanide anti-hyperglycemic agent, which also exerts antiproliferative
effects on cancer cells. This drug inhibits the complex I of the mitochondrial electron trans-
port chain inducing a fall in the cell energy charge and leading 5'-AMP-activated protein ki-
nase (AMPK) activation. AMPK is a highly conserved heterotrimeric complex that
coordinates metabolic and growth pathways in order to maintain energy homeostasis and
cell survival, mainly under nutritional stress conditions, in a Liver Kinase B1 (LKB1)-depen-
dent manner. This work describes for the first time, the in vitro anti-echinococcal effect of
Met on Echinococcus granulosus larval stages, as well as the molecular characterization of
AMPK (Eg-AMPK) in this parasite of clinical importance. The drug exerted a dose-depen-
dent effect on the viability of both larval stages. Based on this, we proceeded with the identi-
fication of the genes encoding for the different subunits of Eg-AMPK. We cloned one gene
coding for the catalytic subunit (Eg-ampkɑ) and two genes coding for the regulatory sub-
units (Eg-ampkβ and Eg-ampkγ), all of them constitutively transcribed in E. granulosus pro-
toscoleces and metacestodes. Their deduced amino acid sequences show all the
conserved functional domains, including key amino acids involved in catalytic activity and
protein-protein interactions. In protoscoleces, the drug induced the activation of AMPK (Eg-
AMPKɑ-P176), possibly as a consequence of cellular energy charge depletion evidenced by
assays with the fluorescent indicator JC-1. Met also led to carbohydrate starvation, it in-
creased glucogenolysis and homolactic fermentation, and decreased transcription of inter-
mediary metabolism genes. By in toto immunolocalization assays, we detected Eg-
AMPKɑ-P176 expression, both in the nucleus and the cytoplasm of cells as in the larval teg-
ument, the posterior bladder and the calcareous corpuscles of control and Met-treated pro-
toscoleces. Interestingly, expression of Eg-AMPKɑ was observed in the developmental
structures during the de-differentiation process from protoscoleces to microcysts. There-
fore, the Eg-AMPK expression during the asexual development of E. granulosus, as well as
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the in vitro synergic therapeutic effects observed in presence of Met plus albendazole sulf-
oxide (ABZSO), suggest the importance of carrying out chemoprophylactic and clinical effi-
cacy studies combining Met with conventional anti-echinococcal agents to test the potential
use of this drug in hydatidosis therapy.
Introduction
Metformin (1,1dimethylbiguanide, Met) is an oral anti-hyperglycemic agent currently used as
the first-choice drug for the treatment of type 2 diabetes, being prescribed to at least 120 mil-
lion people worldwide. The drug is a synthetic compound derived from the natural product
galegine (isoamylene guanidine), extracted from the French lilac or Italian fitch (Galega offici-
nalis) as a herbal medicine [1].
The mechanism of action of Met has been studied in the context of diabetes and Met has
also been associated with the selective killing of cancer cells [2–6], but it is not yet fully eluci-
dated. Metformin may exert its beneficial metabolic actions through the modulation of multi-
ple components. Its primary function is to decrease hepatic glucose production [7] by reducing
the mRNA expression of gluconeogenic genes [2], changing enzyme activities or reducing he-
patic uptake of substrates [6]. Besides, Met inhibits the complex I of the mitochondrial electron
transport chain, which induces a fall in the cell energy charge [8]. The inhibition of complex I
reduces NADH oxidation, lowering the proton-driven synthesis of ATP. Consequently, the
ATP:ADP:AMP equilibrium changes towards increased AMP synthesis by adenylate kinase [9,
10]. Metformin also causes the direct inhibition of AMP deaminase, an enzyme that degrades
AMP [6, 11]. As a result, AMP levels increase, inducing energy crisis (metabolic stress) and
leading to 5'-AMP-activated protein kinase (AMPK) activation [3]. Indeed, Met is recognized
as an indirect activator of AMPK by promoting AMP accumulation. On the other hand,
AMPK enhances translocation of glucose transporters and directly inhibits raptor, a positive
regulator of the target of rapamycin (TOR) in the TOR complex 1 (TORC1) [12]. Also, and in-
dependently of AMPK, Met inhibits TORC1 in a Rag-GTPase-dependent manner [4] and both
mechanisms exert the anti-proliferative effect of the drug.
AMPK is a master coordinator of metabolic and growth pathways, which induces the cata-
bolic processes that produce ATP and inhibits the anabolic, ATP-consuming processes, in
order to restore the cell energy balance. Its primary role lies in the integration of nutrient avail-
ability and environmental stress signals associated with the adaptations required to maintain
cell homeostasis. This protein is a highly conserved serine/threonine kinase which has ortho-
logs in eukaryotic organisms ranging from yeast (sucrose nonfermenting1-SNF1-), round-
worms (AMP-activated kinase-AAK-), and insects to mammals (AMPK) and plants
(Snf1-related kinase1-SnRK1-) [13]. AMPK is an obligate heterotrimeric complex comprising
a catalytic α-subunit and the regulatory subunits β and γ, which is allosterically activated by
AMP and regulated by phosphorylation. The catalytic subunit is highly conserved across
multi-species, with a key threonine residue in the activation loop (Thr210 in SNF1, Thr172 in
AMPK and Thr175 in SnRK1.1), which requires phosphorylation to confer kinase activity. The
β-subunit contains a glycogen-binding domain and a C-terminal domain that mediates the in-
teraction with the α- and γ-subunits of mammalian AMPK [14]. The γ-subunit, with a non-
conserved N-terminal region, is characterized by two pairs of cystathionine-beta-synthase re-
peats that bind adenosine derivates, named Bateman domains. During cell stress, the AMPK
complex can undergo a conformational change in which the γ-subunit disrupts its interaction
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with the catalytic subunit and relieves the inhibition [13]. In mammals, the main upstream ki-
nases are the tumor suppressor Liver Kinase B1 (LKB1), which activates AMPK in response to
energy stress, and the Ca2+/calmodulin-activated protein kinase kinases (especially CaMKKβ
or CaMKK2), which trigger activation in response to increases in cell Ca2+ without requiring
changes in AMP or ADP levels [15]. Through direct phosphorylation, AMPK exerts control
over cellular metabolism and triggers transcriptional reprogramming by recruiting and localiz-
ing various transcription factors, such as the forkhead box O (FoxO) proteins [13]. Thus,
AMPK, as well as its upstream kinase LKB1 and downstream substrates, which shuttle in and
out of the nucleus, can be found both in the nucleus and the cytoplasm [16].
AMPK control increases stress resistance of invertebrate larval stages, such as diapause-like
states of many parasitic and free-living nematodes [17]. In the case of parasitic flatworms such
as the cestode Echinococcus granulosus, whose larval stage causes cystic echinococcosis (CE,
hydatidosis) in humans, the functions of AMPK have not yet been elucidated. Human CE is an
endemic worldwide zoonosis which involves a complex life cycle with an intermediate host
(humans and domestic livestock) and a definitive host (canids). The hydatid cyst or metaces-
tode develops asexually in the intermediate host and produces protoscolex larvae from the
inner germinal layer [18]. Most (>90%) CE cysts occur in the liver, lung, or both organs. The
parasite shows an alternative development in which protoscoleces released into the circulation
after primary cyst surgery or from a ruptured cyst are able to develop into new hydatid cysts,
developing secondary CE [18]. At the moment, benzimidazole carbamates (mebendazole,
albendazole and its main active metabolite, albendazole sulfoxide-ABZSO-) are the most effec-
tive drugs for CE treatment and an alternative to surgery, but the fact that treatment fails in
30–40% of patients encourages the quest for chemotherapeutical alternatives [19]. To develop
strategies for CE treatment and control, it is necessary to highlight basic studies on the parasite
larval stage and to identify possible new molecular targets. In recent studies, we determined
that rapamycin is an effective anti-echinococcal agent and autophagy inducer in E. granulosus
larvae which allowed us to identify TORC1-controlled events in this cestode [20, 21]. Here, we
demonstrate that the E. granulosus larval stage is susceptible to Met in vitro and that Met treat-
ment activates Eg-AMPK. We also discuss the results in relation to carbohydrate metabolism,
autophagy modulation and developmental processes in the parasite.
Material and Methods
Ethics statement
The animal study was performed in strict accordance with National Health Service and Food
Quality (SENASA) guidelines, Argentina and with the 2011 revised form of The Guide for the
Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. All
the experimental protocols were reviewed and approved by the Animal Experimental Commit-
tee at the Faculty of Exact and Natural Sciences, Mar del Plata University (permit number:
2555-08-14).
Experimental animals
Pathogen-free female CF-1 mice (28–35 g), aged 8 weeks, were supplied by the National Health
Service and Food Quality-SENASA-. Mice were allowed to acclimatize for one week before
starting the experiment. The animals were housed in standard polyethylene cages (five mice
per cage) with sawdust (wooden flakes) as nesting material, under controlled laboratory condi-
tions (temperature ±20°C, 12 hour light/12 hour dark with lights off at 8.00 p.m., 55±5% hu-
midity). Water and food pellets were provided ad libitum during the study period. Every 3
days, animals were placed into a clean cage with fresh sawdust.
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E. granulosusmetacestodes were obtained from the peritoneal cavity of mice injected with
0.5 ml of protoscolex suspension. For each experiment, five experimentally infected mice were
killed at 6 months p.i. Animals were anesthetized with ketamine—xylazine (50 mg/kg/mouse—
5 mg/kg/mouse) and sacrificed by cervical dislocation. All efforts were made to minimize suf-
fering. Minimum number of animals was used in each experiment.
In vitro culture of protoscoleces, metacestodes and pre-microcyst
obtainment
E, granulosus protoscoleces were removed under aseptic conditions from hydatid cysts of in-
fected cattle presented for routine slaughter at the abattoir (Liminal S. A., official number:
3879) in the province of Buenos Aires, Argentina. Protoscolex in vitro culture (n = 3,000/
9.5-cm2 growth area per well), pharmacological treatment and vitality assays were performed
as described below. Otherwise, E. granulosusmetacestodes (10–20 cysts for each drug treat-
ment) were obtained from the peritoneal cavities of CF-1 mice after intraperitoneal infection
with protoscoleces [20]. Metformin was purchased from Sigma-Aldrich and ABZSO was kind-
ly provided by C. Salomon, National University of Rosario, Argentina. The drugs were added
to the medium either separately or in combination. In vitro protoscolex and metacestode treat-
ments were assayed with 1, 5 and 10 mMMet, ABZSO alone at 15 μM (equivalent to 4.2 μg ml-
1), and the combination of 1, 5 and 10 mMMet plus 15 μMABZSO for until 15 and 7 days, re-
spectively [21]. In both cases, viability was assessed daily until the viability control was lower
than 90%. Protoscolex viability assessment was determined by the methylene blue exclusion
test [20] and cyst viability measurement was evaluated through an inverted light microscope
having as criteria the collapse of the germinal layers and the cell viability with the trypan blue
exclusion test from a detached germinal membrane. For scanning electron microscopy (SEM),
samples were taken every 24 h and processed as previously described [22]. Each viability exper-
iment was performed using three replicates per treatment condition and repeated three times.
For molecular and biochemical assays, protoscoleces and metacestodes were cultured with 10
mMMet or without drug for 48 h and stored at −80°C until experimental use. Three indepen-
dent experiments were performed for SEM, enzyme activity, RT-qPCR, confocal microscopy,
immunohistochemistry and western blot assays.
In order to obtain vesicularized protoscoleces and pre-microcysts, protoscoleces were cul-
tured in medium 199 supplemented with antibiotics (penicillin, streptomycin and gentamicin;
100 μg/ml), glucose (4 mg/ml), insulin (1.2 U ml-1) and 15% FBS as we described in detail pre-
viously [21]. Development was followed microscopically under an inverted light microscope
every day. Different samples were taken during the pre-microcyst development process and
were used for immunohistochemistry studies.
Enzyme activity analysis and glycogen determination
After two rinses with ice-cold 50 mM Tris—HCl, 0.1–0.2 g of protoscoleces or germinal layers
of 5–10 cyst were homogenized in medium containing 50 mM Tris—HCl, 6 mM β-mercap-
toethanol, 0.3% (v/v) Triton X-100, 1.5 mM EDTA (pH 7.5 at 4°C) and 1 mM PMSF (phenyl-
methylsulfonyl fluoride). The suspensions were frozen in liquid nitrogen and thawed at 37°C
for three cycles. Then, cells were lysed with a homogenizer with Teflon pestle at 0°C in an ice
bath. The homogenate was centrifuged at 100,000 ×g for 15 min and then desalted through
Sephadex G-50 columns before the enzyme activity assays. Protein concentrations were quanti-
fied by Bio-Rad protein assay kit.
Enzyme activities were determined from protoscolex and metacestode protein extracts fol-
lowing the procedure described below. In all cases, the activities were measured at 37°C in a
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recording Shimadzu model UV—vis spectrophotometer, the volume of the reaction mixture
was 1 ml with 50 μl (100 μg protein) of enzyme samples, and measurements were made after
30 min of incubation. Alpha-amylase activity (1,4-α-D-glucan-4-glucanohydrolase; EC 3.2.1.1)
was measured using the 2-chloro-p-nitrophenyl-α-D-maltotrioside (CNP-G3, 2.25 mmol/L)
substrate in 100 mMMES buffer (pH 6.0) with 6 mM calcium acetate, 50 mM sodium chloride
and 10 mM potassium tiocyanate to release 2-chloro-p-nitrophenol (CNP), resulting in
2-chloro-nitrophenyl-α-Dmaltoside (CNP-G2), maltotriose (G3) and glucose [23]. The absor-
bance was read at 405 nm against appropriate blanks and the enzyme activity calculated using
the molar extinction coefficient for CNP. Lactate dehydrogenase was determined by measuring
the formation of the reduced form of nicotinamide adenine dinucleotide (NAD) using 50 mM
lactate and 50 mMNAD as substrates in 400 mMmethylglucamine (MEG, pH 9.4, Wiener
Lab). The rate of NADH formation is directly proportional to the LDH catalytic activity and is
determined by measuring the absorbance increase at 340 nm.
Glycogen extraction and quantification from protoscoleces was performed by completely
hydrolyzing glucose through an overnight digestion with amyloglucosidase and amylase as pre-
viously described [24].
Gene identification, cloning and expression by reverse transcription
(RT)-PCR and quantitative (q)PCR
In order to obtain information on the occurrence of Echinococcus ampk sequences, the E.
multilocularis genomic database and E. granulosus assembled genomic contigs (http://www.
sanger.ac.uk/Projects/Echinococcus) were searched with BLASTp and tBLASTn programs.
Sequences of Homo sapiens and Bombyx mori were used as queries. We identified, sequenced
and deposited in GenBank a single sequence for each putative gene, including ampkα,
ampkβ and ampkγ annotated as EgrG_000708800, EgrG_000526000 and EgrG_001024900
in the GeneDB database (with their respective orthologs in E. multilocularis:
EmuJ_000708800, EmuJ_000526000 and EmuJ_001024900) and they were all identified in
the recently released whole genome sequence of Echinococcus spp. [25]. In addition, homolo-
gous genes coding for glucose-6-phosphatase (G6P), fructose-1, 6-bisphosphatase (F1,6BP),
phosphoenolpyruvate carboxykinase (PEPCK), α-amylase-like glucosidase and LKB1 were
also identified, sequenced and annotated. Specific primers were designed for these genes and
the cytoplasmic malate dehydrogenase (mdhc) gene (S1 Table).
Total RNA extractions, RT-PCR, cloning and qPCR were performed as previously described
[20]. To analyze the levels of gene expression in control and Met-treated parasites, cDNA was
generated from 10 μg of total RNA using Superscript II reverse transcriptase (Invitrogen, Ar-
gentina) and Pfu (Promega, USA) DNA polymerase. RT-PCR and qPCR assays were carried
out under identical reaction conditions: 30 cycle PCRs of 94°C (30 s), 40°C (1 min), and 72°C
(1 min) plus a single step at 72°C for 10 min, their products were analyzed and confirmed as it
was previously described [21]. To determine the optimal amount of template, serial 3-fold dilu-
tions of cDNA were carried out. Under these conditions, RT-PCR amplification occurs in the
linear range. E. granulosus actin I (actI, GenBank accession no. L07773) was used as an internal
control. For qPCR, the calculation of the ratio between the actI mean Ct-values in the treated
and control sample showed no significant change in gene expression between both samples
[26], thus providing a useful internal control in this experiment. The levels of mRNA were nor-
malized to the actin expression level and calculated using the 2(-ΔΔCT) method. Melting curves
generated ensure the correct amplification of all genes tested in this work when using the de-
signed primers (S1 Table). PCR amplification efficiency values were near to 96% and the
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correlation coefficients (r2) between the logarithm of the cDNA starting quantity and the Ct
were, at least, 0.95 for all genes.
Sequence analysis
Ortholog selection was based on reciprocal best BLAST hits and the presence of the character-
istic domains in each deduced amino acid sequence. Sequence alignments were generated with
the CLUSTALX software program. Nuclear localization signal was predicted with cNLS Map-
per Prediction (http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi).
Studies of Mitochondrial Membrane Potential (ΔΨm)
Control and Met-treated protoscoleces in different times (6-12-24-36 and 48 h) were incubated
with 10 mg/mL JC-1 dye for 30 min at room temperature. After incubation, parasites were
washed with 20 mMHEPES buffer, pH 7.2, and images were taken using a confocal microscope
(Nikon Eclipse C1 Plus). The intensities of green (excitation/emission wavelength = 485/538
nm) and red (excitation/emission wavelength = 485/590 nm) fluorescence were analyzed for
20 individual protoscoleces from control and treated-samples. Images were analyzed using
Image J software (NIH). The ratio of red to green fluorescence of JC-1 images was calculated
using NIH Image J software (http://rsb.info.nih.gov/ij/).
Western blot analysis and immunohistochemistry
Polypeptides were separated by SDS—PAGE on 10% polyacrylamide gels and electroblotted
onto a nitrocellulose membrane (HyBond C; Amersham, Argentina) as previously described
[20]. The membranes were incubated with primary monoclonal antibodies directed against
phosphorylated and total human AMPKα [Phospho-AMPKα -Thr172- (40H9) Rabbit mAb
and AMPKα (D63G4) Rabbit mAb, Cell Signalling cat no. 2535 and 5832, respectively, USA,
1:1000 dilution] or with primary monoclonal antibody against human actin (JLA-20, Develop-
mental Studies Hybridoma Bank-DSHB, USA, 1:2000 dilution) as a control for protein loading.
The anti-AMPKα antibody used in these assays is directed against an epitope which showed
90–97% amino acid identity with the possible ortholog of E. granulosus. Then, the membranes
were incubated with anti-rabbit immunoglobulin (Ig) peroxidase-linked, species-specific whole
antibody (GE Healthcare, cat no. NA934V). ECL reagents were used to detect the signals ac-
cording to the manufacturer’s instructions (GE Healthcare, cat no. RPN2106V1). Chemilumi-
nescence was detected on film and quantified using Image J. To correct any possible unequal
loading, each band's density was normalized to its actin density or total target protein. Eg-
MDH immunodetection was performed as previously reported [24]. Blots were quantified
using an imaging analyzer (Fotodyne model express zoom lens system) and its dedicated soft-
ware (TotalLab image analysis software) and normalized against actin density.
In parallel, for in toto immunohistochemistry, pre-microcysts and control and Met-treated
protoscoleces were processed as previously described [21]. Negative controls consisted of omis-
sion of primary antibody.
Statistics
The mRNA expression in protoscoleces and metacestodes was analyzed with the Wilcoxon
signed rank nonparametric test. Data within experiments were compared; significance was de-
termined using the student’s t test and P< 0.05 was considered statistically significant. All data
are shown as the arithmetic mean ± SEM.
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Results
Pharmacological sensitivity of E. granulosus protoscoleces and
metacestodes to metformin and its combination with albendazole
sulfoxide
To investigate the in vitro effect of Met on the viability of E. granulosus larval stages, the death
percentage of protoscoleces and metacestodes was analyzed in response to various Met concen-
trations. As shown in Fig 1A and 1B, 10 and 4 days exposure led to a dose-dependent decrease
in the viability of protoscoleces and metacestodes, respectively. At 10 mMMet, 80±5% of pro-
toscoleces were dead and 55±5% of metacestodes had disintegrated germinal layers (Fig 1A–
1C). During the same time, at 1 mMMet, protoscoleces revealed no changes in vitality in com-
parison to the control and only 10±2% of metacestodes were dead. In addition, Met-induced
damage was observed by SEM after 4 days of treatment with 10 mM drug. In treated protosco-
leces, the scolex region was contracted (Fig 1Dc) and rostellar disorganization, loss of hooks
and shedding of microtriches were observed (Fig 1Dd), whereas control cultures exhibited no
ultrastructural alterations in parasite tissue during the whole incubation period (Fig 1Da-b).
Metformin-treated metacestodes revealed loss of cells in the germinal membrane of cysts (Fig
1Dg-h), whereas control metacestodes exhibited an intact germinal layer comprised of a multi-
tude of different, morphologically intact, cell types (Fig 1De-f).
Furthermore, an increased anti-echinococcal effect was found when a combination of Met
plus ABZSO was used (Fig 1A and 1B). In this case, 1mMMet plus 15 μMABZSO (equivalent
to 4.2 μg/ml) increased the protoscolex mortality to 30±2% after 10 days of incubation com-
pared with each drug alone, (it was only 20±2% with ABZSO and it did not change with Met).
In the case of metacestodes, the mortality increased to 45±5% with 1mMMet plus 15 μM
ABZSO in comparison with 20±5% with ABZSO alone 4 days post-incubation.
Carbohydrate metabolism modifications induced by metformin in
E. granulosus larval stages
To analyze the effect of Met on energy-generating mechanisms in the parasite larvae, we investi-
gated the glycogen levels and the expression and activity of enzymes with a key role in cellular
metabolism. A concentration of 10 mM ofMet for 48 h revealed low toxicity since the proportion
of viable protoscoleces was similar to that of the control (94 ± 3% vs 99%, respectively). However,
Met-treated protoscoleces showed a significant decrease in the glycogen level (5.0 ±1.5 mg/g
FW-fresh weight-) compared with the control (20± 4 mg/ g FW). In agreement with glycogen
degradation, α-amylase and lactate dehydrogenase activities increased upon drug treatment in
both larval stages, with a more pronounced percental change in protoscoleces than in metaces-
todes (Fig 2A and 2B). In addition, in the the E. granulosus assembled genomic contigs, we iden-
tified an ortholog to the Schistosoma japonicum α-amylase-like glucosidase gene (CAX75459),
which coding sequence was annotated as JN038062 in GenBank (corresponding to Eg-amyl
gene). The predicted protein sequence (named Eg-α-amylase and annotated as AEJ15816 and
EgrG_000494800 in the GenBank and GeneDB database respectively) aligned with at 40% and
35% identity with the S. japonicum and Aspergillus oryzae (0901305A, Taka-Amylase A) ortho-
logs, respectively. E. granulosus-α-amylase shows three of four catalytic residues invariantly con-
served throughout the α-amylase family (pfam00128), corresponding to Asp229, Glu258 and
Asp323 and motifs characteristic in six of the seven conserved regions (S1 Fig) [27].
We also analyzed the expression of the Eg-f1,6bp (annotated as JN038064 in GenBank), Eg-
pepck (annotated as JN038060), Eg-g6p (annotated as JN038058) and Eg-mdhc genes from proto-
scoleces and metacestodes. RT-PCR showed a considerable decrease in these transcripts in
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Met-treated protoscoleces in comparison with the control group (Fig 2C). By qPCR, we found that
the transcript levels for Eg-f1,6bp, Eg-pepck, Eg-g6p and Eg-mdhc decreased three-, four-, two- and
three-fold in Met-treated protoscoleces and three-, five-, one- and two-fold in Met-treated meta-
cestodes, respectively (Fig 2D). In concordance with gene expression, immunoanalysis of the Eg-
MDH polypeptide level showed a considerable decrease in treated protoscoleces respect to the con-
trol (c.a. 30% of the control estimated by densitometric analysis normalized to actin, Fig 2E).
Fig 1. Effect of metformin and its combination with albendazole sulfoxide on viability and
ultrastructural characteristics of protoscoleces andmetacestodes of E. granulosus. Viability of
protoscoleces (A, PTS) and metacestodes (B, MTC) incubated for 10 and 4 days, respectively with 1, 5 and
10 mM of metformin alone (Met, gray bars), 15 μM albendazole sulfoxide (ABZSO, black bars) alone and 1, 5
and 10 mMMet plus 15 μMABZSO in combination (open bars). Data are the mean ± S.D. of three
independent experiments. ***Statistically significant difference (P < 0.05) compared with control. (C)
Macroscopical damage of metacestodes treated with 10 mMMet for 4 days. Control metacestodes (Co)
without morphological changes and treated metacestodes showing increased permeability (culture medium
inside cysts) and collapsed germinal layer (circles). (D) Scanning electron microscopy of protoscoleces (a-d)
and metacestodes (e-h) incubated with 10 mM of Met for 4 days. Control protoscolex with normal sucker and
microtriches (a,b); treated protoscolex with soma region contracted and scolex region showing loss of hooks
and shedding of microtriches (c,d); control murine cyst with an intact germinal layer (e,f); treated cyst with
altered germinal layer (g,h). Bars indicate: 10 μm in (b, d and g-h), 20 μm in (a, c and f) and 50 μm (e).
doi:10.1371/journal.pone.0126009.g001
Metformin Effects and AMPK Characterization in Echinococcus granulosus
PLOSONE | DOI:10.1371/journal.pone.0126009 May 12, 2015 8 / 23
Fig 2. Metabolic and transcriptional changes induced by 10mMmetformin in parasites treated for 48 h. Analysis of Eg-α-amylase (A) and Eg-lactate
dehydrogenase (LDH) (B) activities in protoscoleces (PTS) and metacestodes (MTC). (C) Reverse Transcription (RT)-PCR analysis from total RNA of control
(Co) or treated (Met) protoscoleces. Amplification of Eg-actin I (actI) was used as a loading control. Molecular sizes of amplicons are indicated with
arrowheads. Eg-f1,6bp: fructose-1,6-bisphosphatase, Eg-pepck: phosphoenolpyruvate carboxykinase, Eg-g6p: glucose-6-phosphatase, Eg-mdhc:
cytoplasmic malate dehydrogenase. (D) Quantitative PCR analysis from total RNA of protoscoleces (PTS) and metacestodes (MTC) treated with Met
compared to controls. Fold change expression values are plotted. Data are the mean ± S.D. of three independent experiments. ***Statistically significant
difference (P < 0.05) compared with control. (E) Immunoblot of Eg-MDH revealed with a polyclonal antibody. Total protein extracts from control (Co) and Met-
treated protoscoleces (Met) were loaded at 100 μg of total protein/lane. Actin was used as a loading control. Polypeptide size is shown.
doi:10.1371/journal.pone.0126009.g002
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Changes in mitochondrial membrane potential of protoscoleces exposed
to metformin
To explore the possible inhibitory effect of Met on the complex 1 of the respiratory chain, we
studied the mitochondrial functional status using the membrane potential (ΔCm) indicator
JC-1 in E. granulosus protoscoleces. JC-1, a positively charged fluorescent compound, can pen-
etrate mitochondria and change their color when the membrane potential increases. In normal
mitochondria with high ΔCm, JC-1 accumulates as aggregates with intense red fluorescence,
whereas in damaged mitochondria with low ΔCm, it remains in the monomeric form, which
exhibits only green fluorescence [28].
Control and Met-treated protoscoleces were examined by confocal microscopy for JC-1
fluorescence. The mitochondrial membrane potential in control protoscolex cells was heteroge-
neous between 6 to 36 h of Met-treatment. Only following 48 h Met treatment, the energetic
state of parasite cells was metabolically synchronized and the relative values of red/green JC-1
fluorescence ratios showed low dispersion. At this point, untreated protoscoleces showed a
ratio of red to green fluorescence with a mean value of 3.1 (Fig 3Aa-d and 3B), whereas Met-
treated protoscoleces showed a lower mean ratio of around 1.2 (Fig 3Ae-h and 3B). Metformin
treatment induced an increase in depolarized regions indicated by the disappearance of red
fluorescence and an increase in green fluorescence (Fig 3Ae-h).
Occurrence and expression of genes encoding E. granulosus AMPK
Maintaining mitochondrial membrane potential is required for ATP production. By depolariz-
ing mitochondria, Met may increase the cellular AMP:ATP ratio and modulate AMP- or ADP-
sensitive enzymes such as AMPK. To investigate this possibility, we first analyzed the occur-
rence of the three subunits of AMPK in E. granulosus larval stages.
Extensive BLASTp searches on the available E.multilocularis genome and the incompletely
assembled E. granulosus genome revealed three genes coding for the different subunits of
AMPK (S2 and S3 Figs). The selection of orthologs was based on reciprocal best hits in BLAST
searches, using an E-value cutoff1e-25. These coding regions were cloned, fully sequenced and
annotated in GenBank (JF412830-Eg-ampkα-, JF412832-Eg-ampkβ- and JF412834-Eg-ampkγ-
). The genes encode a 478-amino acid protein (named Eg-AMPKα and annotated as
AER10553), a 290-amino acid protein (named Eg-AMPKβ and annotated as AER10555) and a
340-amino acid predicted protein (named Eg-AMPKγ and annotated as AER10557). We con-
firmed by RT-PCR that the three genes identified were transcribed in protoscoleces and meta-
cestodes (Fig 4A). The deduced amino acid sequences for the three subunits of the E.
granulosus AMPK showed that all domains corresponding to specific functions were conserved,
including key amino acids involved in protein-protein interactions (Fig 4B, S2 and S3 Figs).
The predicted Eg-AMPKα sequence aligned with 56, 61 and 97% identity with the H. sapi-
ens (NP_006243), Bombyx mori (ABQ62953) and E.multilocularis (AER10552) orthologs, re-
spectively (Fig 4B and S2A Fig). The Eg-AMPKα subunit presents a conserved N-terminal
kinase domain as well as a β-subunit interaction domain (β-SID), which is found near the C-
terminal end and is followed by a conserved nuclear export sequence. It also presents a highly
conserved threonine residue in the activation loop of the kinase domain (Thr176), which is a
potential phosphorylation site that could modulate the enzymatic activity. On the other hand,
Eg-AMPKβ aligned with 54, 58 and 99% identity with theH. sapiens (NP_005390), B.mori
(NP_001103403) and E.multilocularis (AER10554) orthologs, respectively (Fig 4B and S2B
Fig). The Eg-AMPKβ subunit consists of a glycogen-binding domain, which is located in the
middle of the protein and contains conserved key residues for their interaction with glycogen
in both identity and position. At its C-terminal end, this protein also contains a conserved
Metformin Effects and AMPK Characterization in Echinococcus granulosus
PLOSONE | DOI:10.1371/journal.pone.0126009 May 12, 2015 10 / 23
domain that presumably mediates the interaction with both the α and γ subunits of AMPK
(αγ-SID). Finally, the Eg-AMPKγ subunit showed 56, 48 and 82% identity with theH. sapiens
(P54619), B.mori (NP_001119720) and E.multilocularis (AER10556) orthologs respectively,
and it contains the cystathionine-beta-synthase repeats that constitute the Bateman domains,
with the residues involved in nucleotide binding (Fig 4B and S3 Fig).
Pharmacological activation of Eg-AMPKα and immunolocalization in
protoscoleces
Metformin might activate Eg-AMPK as a consequence of cellular energy charge depletion.
Thus, we studied the phosphorylation at Thr176 of Eg-AMPKα (AMPKα-P176) as a read-out of
its activation state (Fig 5A). For that, immunoassays using rabbit monoclonal antibodies direct-
ed against the total and phosphorylated form of human AMPKα (Thr172) were performed
from protein extract of protoscoleces and signals were normalized to total AMPKα and to
actin detection (Fig 5B). We showed that a significant increase in the Eg-AMPKα-P176 level
Fig 3. Metformin pharmacological effect on mitochondrial function in protoscoleces. (A) Representative confocal images showing JC-1 fluorescence
in protoscoleces incubated under control conditions (a-d) or treated with 10 mMmetformin (Met, e-h) for 48 h. tg: tegument; rc: rostellar cone; su: sucker; pb
posterior bladder. Bars indicate 50 μm. (B) Boxplot graph showing the values of the red/green JC-1 fluorescence ratios measured in control (Co) and Met-
treated protoscoleces by Image J Software. ***Statistically significant difference (P < 0.05) compared with control.
doi:10.1371/journal.pone.0126009.g003
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was observed after 48 of treatment with 10 mMMet indicating Eg-AMPKα activation under
this condition. The bands were not observed when the strips were incubated with the second-
ary antibody alone (data not shown).
By in toto immunolocalization assays from protoscoleces, the expression of total and
phosphorylated Eg-AMPKα forms was detected in the tegument, the posterior bladder and
surrounding the calcareous corpuscles (Fig 5C). In addition, both forms were observed in the
nucleus and in the cytoplasm of the cells of Met-treated and control samples (S4 Fig and data
not shown), although in Met-treated protoscoleces the tegumental and nuclear Eg- AMPKα-
P176 expression was higher than in the control condition (Fig 5Cb-d). This is consistent with
the presence of a nuclear export sequence at the C-terminus of the catalytic subunit of Eg-
AMPK and its direct involvement in transcriptional regulation. The fluorescence pattern was
not observed when the parasites were incubated with the secondary antibody alone (data not
shown).
Finally, an ortholog to human LKB1, the main kinase phosphorylating the AMPK activation
loop under conditions of energy stress, was identified and shown to be constitutively expressed
in E. granulosus larval stages (S5A Fig). Its predicted sequence showed 37, 37 and 94% identity
with the H. sapiens (Q15831), B.mori (NP_001119722) and E.multilocularis
(EmuJ_000365800) orthologs, respectively. Eg-LKB1 contains a conserved kinase domain and
a nuclear localization signal at the N-terminal half of the molecule, a regulatory domain at the
C-terminal and one key residue involved in autophosphorylation (T324, S5B–S5C Fig).
Fig 4. Expression and structural features of the subunits of E. granulosusAMPK. (A) Reverse
transcription-PCR analysis of the three subunits of Eg-AMPK (α, β and γ) from total RNA of protoscoleces
(PTS) and metacestodes (MTC). Amplification of Eg-actI was used as a loading control. Molecular sizes of
amplicons are indicated with arrowheads. (B) Schematic representation of Homo sapiens AMPKα1, AMPKβ2
and AMPKγ1, and of the predicted AMPK protein from the E. granulosus genome. Identification of kinase
domain, β-subunit interaction domain (β-SID), autoinhibitory sequence (AIS), α-hook (α-H) and nuclear
exportation sequence (black box) in the catalytic subunit; glycogen-binding domain (GBD) and α- and β-
subunits interaction domain (αγ-SID) in the β-regulatory subunit; and divergent N-terminal domain (γNTD)
and cystathionine-beta-synthase repeats (CBS 1–4) in the γ-regulatory subunit.
doi:10.1371/journal.pone.0126009.g004
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Fig 5. Detection and immunolocalization of total and phosphorylated Eg-AMPKα forms from E.
granulosus protoscoleces. (A) Representative immunoblots of Eg-AMPKα and Eg-AMPKα-P176 revealed
with heterologous antibodies against the total and phosphorylated forms of human AMPKα are shown. Total
protein extracts from control (Co) and 10 mMmetformin-treated protoscoleces (Met) were loaded at 100 μg of
total protein/lane. Both Eg-AMPKα and Eg-AMPKα-P176 were detected (see in S2A Fig the epitopes
recognized by each antibody). Polypeptide sizes are shown. (B) Graphs depict the fold change in the p-
AMPK/AMPK. Densitometric analysis of Eg-AMPKα-P176, normalized to total AMPKα (left) and normalized to
actin (right) in protoscoleces treated with 10 mMMet relative to controls (3 independent experiments with
3000 protoscoleces per sample). Values are expressed as means ± SEM (p < 0.05 compared to control). (C)
Confocal images of in toto immunolocalization assays revealed with an antibody conjugated with Alexa 488
—green fluorescence- and counterstained with propidium iodide—red fluorescence-. Control (a,b) and Met-
treated protoscoleces (c,d) incubated with anti-AMPKα antibody (a,c) or anti-AMPKα-P antibody (b,d).
Cytoplasmic expression is observed in green (arrows). Nuclear expression is observed in yellow/orange,
corresponding to the merged fluorescences (arrowheads). Inset images correspond to transmission
microscopy. tg: tegument; su: sucker; cc: calcareous corpuscle. Bars indicate 50 μm.
doi:10.1371/journal.pone.0126009.g005
Metformin Effects and AMPK Characterization in Echinococcus granulosus
PLOSONE | DOI:10.1371/journal.pone.0126009 May 12, 2015 13 / 23
Expression pattern of Eg-AMPKα during microcyst development
Under controlled in vitro culture conditions, protoscoleces of E. granulosus can progress in the
cystic direction through different mechanisms [29] (see Fig 6A). Cysts can develop from evagi-
nated or invaginated protoscoleces, from free posterior bladders or even from everted brood
capsules. To evaluate the expression of Eg-AMPKα during the in vitro differentiation of
Fig 6. Immunolocalization of Eg-AMPKα during the in vitro de-differentiation process of
protoscoleces to microcysts. (A) Diagrammatic representation of the different mechanisms involved in cyst
development during in vitro culture. Image reconstructed using the figure published by Rogan and Richard
(1986) [29]. This image is similar but not identical to the original image, and is therefore for illustrative
purposes only. (B) Transmission and confocal microscopy of a brood capsule (a,b), an everted brood capsule
(c,d), protoscoleces with posterior bladders (e,f), developing cysts from posterior bladders (g-j), vesicularized
protoscoleces (k-p) and pre-microcysts developed from vesicularized protoscoleces (q-x). bc: brood capsule;
ebc: everted brood capsule; pb: posterior bladder; st: stalk; nu: nucleus; dh: disrupted rostellar hook; broken-
lined box indicates stalk portion; solid-lined boxes indicate distribution of nuclei in vesicularized
protoscoleces. Bars indicate 200 μm (b and d) and 100 μm (f, h, j, l, o, r and u).
doi:10.1371/journal.pone.0126009.g006
Metformin Effects and AMPK Characterization in Echinococcus granulosus
PLOSONE | DOI:10.1371/journal.pone.0126009 May 12, 2015 14 / 23
protoscoleces into microcysts, we carried out in toto immunolocalization assays in samples col-
lected from the same culture at different times. We were able to detect different morphological
states involved in cyst development such as intact or everted brood capsules (Fig 6Ba-d), proto-
scoleces with posterior bladders (Fig 6Be-f), developing cysts from posterior bladder (Fig 6Bg-
j), vesicularized protoscoleces (Fig 6Bk-p) and pre-microcysts developed from vesiculating pro-
toscoleces (Fig 6Bq-x). The expression pattern of Eg-AMPKα in the structures formed during
the de-differentiation process from protoscoleces was observed (Fig 6B). No signal was de-
tected in the control samples that were only incubated with the secondary antibody under the
same conditions (data not shown).
The first nuclei of the developing cyst were observed in the posterior bladder, formed from
reminiscent stalk (Fig 6Bg-h). In this developmental stage, we observed high Eg-AMPKα ex-
pression on the periphery of this structure (Fig 6Be-h). Then, an increase in the number of nu-
clei was observed and the Eg-AMPKα expression became diffuse mainly restricted to the
developing cyst (Fig 6Bi-j). On the other hand, the metamorphic events that takes place in vesi-
cularized protoscoleces during microcyst development was also associated with changes in Eg-
AMPKα expression (Fig 6Bk-s, the vesicular differentiation begins with diffuse and generalized
fluorescent signal and follows with a spotted and localized expression). Finally, the pre-micro-
cyst conserved the expression of this protein and non-specific fluorescent signal was detected
in the disrupted rostellar hook (Fig 6Bt-x).
Discussion
Chemotherapeutic attack on the energy-generating systems of parasites is a rational approach
to fight parasitic infections, given that energy in the form of ATP is a commodity that these or-
ganisms cannot directly obtain from the host [30]. We reported for first time, the in vitro sus-
ceptibility of E. granulosus larval stages to a biguanide. In short-term assays, Met showed anti-
echinococcal effects on parasites maintained in a nutrient-repleted medium, where high con-
centrations of the drug (starting from 1 mM in metacestodes and from 5 mM in protosoco-
leces, Fig 1A–1C) are required in order to affect the energy-generating systems and to interfere
with the regulation of the AMPK/TOR axis, after crossing the tegumental system and to
achieve the tissue distribution [31]. In this regard, doses in the millimolar range may be re-
quired to accomplish cell death effects in different human cancer cell lines [32–37]. In addition,
since Met exhibits a hydrophilic nature and a slow absorption kinetic, it is considered a com-
pound with scarce efficacy [3]. However, its combination with classic chemotherapeutic drugs
allows the use of lower doses [38, 39]. Taking into account the structural and cellular differ-
ences with helminths, it has been reported that in protozoan parasites different biguanides
(proguanil, chlorproguanil, synthalin, and Met) showed in the micromolar range synergistic
action with atovaquone, both drug types associated with reductions in mitochondrial function,
resulting in cellular damage and death [40]. In the same line of evidence, our in vitro pharma-
cological experiments showed an improved anti-echinococcal activity of Met in combination
with low-dose ABZSO, compared with both drugs alone (Fig 1A and 1B). Likewise, it was nec-
essary to use at least 1 mMMet to achieve the in vitro therapeutic effect. Therefore, the true bi-
ological effects of this drug can be resolved with further in vivo assays, including also
combinations of Met with conventional anti-echinococcal agents such as benzimidazoles.
Since Met is actively transported into cells by the organic cation transporters, called OCT1/
OCTN1 or SLC22A1/4 [41, 42], the accumulation of the drug is significantly higher in tissues,
particularly in gut and liver (~ 200 μmol/kg wet weight of tissue) than in plasma (~ 30–50 μM)
[43], achieving micromolar levels in hepatocytes of the periportal zone [33, 43, 44]. In this
work, we identified the putative OCTs (EgrG_001058900 and EgrG_000957000) in the E.
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granulosus genome, which displayed structural similarities and 25% identity with the H. sapi-
ens ortholog. Given that the liver is the main tissue of action of Met and a target organ in hyda-
tidosis, it will be interesting to carry out effectiveness studies of Met with in vivomodels using
a Met concentration that can be safely obtained in the clinical setting (50 mg/kg day) [43],
which will give us better insights into the action of this drug in the cestode.
In human cell culture and in xenograft models, Met can interfere with cell cycle progression,
leading to G0/G1 or S phase arrest, through a decrease in cyclin D1 protein levels [32]. Howev-
er, the most accepted anti-proliferative effect of Met is via regulation of the AMPK/TOR axis
under control of LKB1 [45–47]. In consequence, the suppression of TORC1 signaling by
AMPK agonists has therapeutic implications for the treatment of human cancer using existing
FDA-approved agents [48]. Since we have previously reported conserved TORC1 in Echinococ-
cus [20, 21], in this work Met was used as the first criterion to identify AMPK-controlled events
in Echinococcus larval stages. Based on the drug susceptibility and using information obtained
from the Echinococcus genome project, one gene encoding for the catalytic subunit (Eg-ampk)
and for each regulatory subunit (Eg-ampk and Eg-ampk) were identified and their constitutive
expression verified, which allowed us to clone their transcripts (Fig 4, S2 and S3 Figs). Addition-
ally, in accordance to what was found by Zheng et al. [49], our results showed that the genes en-
coding Eg-AMPK subunits have a higher expression level in protoscoleces when compared to
metacestodes (Fig 4A). Their predicted proteins, as well as the putative Eg-LKB1 protein, show
considerable evolutionary conservation of the sites interacting with each other, according to
their mammalian counterparts (S2, S3 and S5 Figs). Besides the Echinococcus ampk genes cited
in this work, an additional gene encoding each regulatory subunit has been reported by Tsai
et al. [25]. Regarding the ampk gene number, one catalytic subunit, three β-subunits and one γ-
subunit have been identified in the yeast genome. On the other hand, Caenorhabditis elegans
andH. sapiens have two α-, two β-, and five and three γ- gene orthologs, respectively, while in
Drosophila melanogaster, each subunit is encoded by a single gene. Since AMPK functions nor-
mally and is stable as a heterotrimeric complex, the number of genes in each organism deter-
mines how many complexes can possibly be formed in each of them [13].
It has been demonstrated that AMPK is indirectly activated by Met as a consequence of re-
spiratory chain complex I inhibition [9]. Indeed, the subcellular target of Met is the mitochon-
drion, in which the membrane potential might drive the accumulation of the positively charged
drug within the organelle matrix. Following treatment with Met in the presence of JC-1 dye, the
number of mitochondria that exhibited a low red/green ratio was markedly increased in Echino-
coccus protoscoleces (Fig 3). These findings indicate that Met causes mitochondrial membrane
depolarization and could inhibit the complex I of the electron transport chain, in accordance
with previous reports [9, 40, 50]. In fact, it has been previously reported that impairment of mi-
tochondrial respiration by complex I blockade with nafuredin and quinazoline-type com-
pounds in Ascaris suum and E.multilocularis also shows anti-parasitic effects [51–53].
In E. granulosusMet-treated protoscoleces, a decreased mitochondrial ATP production
might induce an increase in larval AMP levels and subsequent Eg-AMPK activation through
phosphorylation on T176 (Fig 5A and 5B), potentially via Eg-LKB1. The ATP:AMP ratio of the
Echinococcus protoscoleces has been reported to be in the range of 0.86–0.92, the highest value
recorded for a parasite [54]. Nevertheless, in our study, the high Eg-AMPK activity in the pro-
toscolex basal state might reflect an increased AMP content, even under nutrient-rich condi-
tions. On the other hand, a decrease in oxidative phosphorylation is equivalent to nutrient
depletion in terms of ATP supply and could force the cells to engage survival processes such as
increased glycolysis and autophagy [55]. Since AMPK promotes autophagy from yeast to
mammals [56–58], further experiments with hydatid fluid and different starvation conditions
should be carried out to study AMPK/TOR signal pathways in this cestode.
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As a consequence of reduced ATP production, glycolysis and glycogenolysis are stimulated.
Indeed, both catabolic processes increase in Met-treated mammalian cells [59]. In this line of
evidence, we showed that Met induces a decrease in glycogen levels, the major energy reserve
in parasite tissue, and an increase in Eg-α-amylase and Eg-LDH activities, indicating an in-
crease in these catabolic processes in Echinococcus larval stages (Fig 2A and 2B). On the other
hand, our results also showed a decreased expression of Eg-pepck, which encodes a CO2-fixing
enzyme that participates in the glycolytic pathway of parasitic helminthes [30, 60, 61], and Eg-
MDHc, a critical enzyme in the malate—aspartate conversion, both key enzymes in the inter-
mediary metabolism of cestodes [30, 62]. This could be affecting the generation of cytosolic
and mitochondrial NADH/NAD+, further compromising the ATP pools in EchinococcusMet-
treated cells and causing metabolic exhaustion in the parasite. Also, we demonstrated that Eg-
g6p and Eg-f1,6bp are down-expressed in drug-treated protoscoleces and metacestodes (Fig 2C
and 2D). In this regard, the transcription of genes encoding two key hepatic gluconeogenic en-
zymes, PEPCK and G6P is inhibited in rat hepatocytes by Met-dependent activation of AMPK
[59, 63, 64]. Given that, in parasitic helminthes the physiological role of PEPCK is the carboxyl-
ation of phosphoenolpyruvate to form oxaloacetate, it is not comparable to its function in
mammals, where the enzyme catalyzes the inverse reaction during the gluconeogenesis [30,
65]. Although these parasites rely on stored glycogen for energy, the occurrence of gluconeo-
genesis has not been demonstrated in Echinococcus larval stages yet, nor has the transcription
of carbon-metabolism related genes been studied.
In particular, the simultaneous action of glycogenolysis, homolactic fermentation and ma-
late dismutation are linked to the Warburg effect in Echinococcus cyst germinal cells, facilitat-
ing the uptake and incorporation of nutrients into the biomass during cell division [65].
Indeed, the germinal layer converts most glucose to lactate through aerobic glycolysis, regard-
less of whether oxygen is present. Notably, AMPK has been shown to negatively regulate the
Warburg effect in vivo, the change from oxidative metabolism to glycolysis frequently detected
in tumor cells [6, 66]. This could be another cause of the pharmacological effect of Met on E.
granulosusmetacestodes (Fig 1B). Since Eg-AMPKα expression was detected during the differ-
entiation of protoscoleces towards microcysts (Fig 6B), this drug also could represent an anti-
echinococcal alternative during the development of secondary hydatidosis.
Finally, the subcellular expression of AMPK has important functional consequences de-
pending on the substrate location. In coordination with AMPK-dependent events, LKB1 kinase
also shuttles in and out of the nucleus [16]. Here, we demonstrated by in toto immunoassays
that total and phosphorylated Eg-AMPKα was expressed both in the nucleus and cytoplasm of
the cells (Fig 5C and S4 Fig). This is consistent with the presence of a nuclear export sequence
in both Eg-AMPKα and Eg-LKB1 (S2A and S5B Figs). Thus, AMPK-downstream actions
could exert a dual control over cellular metabolism and transcriptional regulation [13]. At nu-
clear level, in mammalian cells and worms, AMPK affects the transcription by phosphorylation
of various transcription factors, such as FoxO family proteins [15, 67]. Recently, we identified a
single FoxO transcription factor in the E. granulosus genome [21] verifying that its amino acid
sequence presents the six potential conserved phosphorylation sites for Eg-AMPK (T278, S509,
S522, S647, S680, S714), as it happens in mammals [67, 68].
Given its sensitivity to the energy state of the cell and the whole organism, AMPK could be
highly relevant to parasitic helminths, which adjust their metabolism to a low rate of ATP turn-
over [69, 70]. Thus, the understanding of the nature of different carbohydrate-energy regulato-
ry mechanisms in these parasites represents a solid basis for choosing appropriate targets for
new chemotherapeutic agents.
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Supporting Information
S1 Table. Primers used to amplify encoding genes for LKB1, AMPK, G6P, F1,6BP, PEPCK
and MDHc in E. granulosus.
(DOC)
S1 Fig. Multiple sequence alignment of α-amylase proteins including E. granulosus. Con-
sensus is indicated in the last line, total (uppercase letter), conservative changes (numeral) and
absence of consensus (dots) and gaps introduced to maximize the alignment (dashes). Charac-
teristic catalytic residues Asp229, Glu258 and Asp323 are indicated with arrowheads and six of
the seven characteristic motifs of the conserved regions of Taka-amylase A are indicated with
boxes [27]. GenBank accession numbers for the α-amylase proteins are: Taka-amylase-A, As-
pergillus oryzae (0901305A) and Eg-α-amylase E. granulosus (AEJ15816).
(TIF)
S2 Fig. Multiple sequence alignment of AMPKα (A) and AMPKβ (B) orthologs including
Echinococcus spp. Consensus is indicated in the last line, total (uppercase letter), partial
(lowercase letter), conservative changes (asterisk), absence of consensus (dots) and gaps in-
troduced to maximize the alignment (dashes). (A) Catalytic subunit of Eg-AMPK shows a
characteristic phosphorylation site (Thr176 black arrowhead) surrounded by a highly con-
served region (gray box, coincident with the amino acids that recognizes the Phospho-
AMPKα antibody utilized in the immunoassays), a segment called α-hook (link between the
kinase domain and the C-terminal regulatory fragment) that might interact with the γ-subunit
(double dotted-underlined, 349–355) [71], an autoinhibitory sequence (solid-underlined,
298–335) which might bind to the kinase domain through of conserved residues in both re-
gions (L74, R76, Y133, R136, R266 indicated by numeral and V299, L314, L323, L329, D332, N333 indi-
cated by arrows), [72] and a C-terminal nuclear export sequence (NES) (broken-lined box,
465–478 with key leucine-L472, L476- indicated by arrows) [16]. In addition, in the alignment is
indicated with a solid box, the amino acid region (surrounding Lys40-white arrowhead- of
human ortholog) that recognizes the total AMPKα antibody utilized in the immunoassays.
GenBank accession numbers for the AMPKα proteins are: Bm, Bombyx mori (ABQ62953),
Hs, Homo sapiens (NP_006243), Eg, Echinococcus granulosus (AER10553) and Em, Echinococ-
cus multilocularis (AER10552). (B) Eg-AMPKβ consists of a glycogen binding domain (under-
lined, 118–173) with conserved key residues (W118, S129, K147, W154, N172, indicated by
arrows) [73], an N-terminal consensus sequence for myristoylation (MGNXXS/T, gray box)
associated with facilitating membrane binding [74] and a conserved H253 (arrowhed). Gen-
Bank accession numbers for the AMPKβ proteins are: Bm, Bombyx mori (NP_001103403),
Hs, Homo sapiens (NP_005390), Eg, Echinococcus granulosus (AER10555) and Em, Echinococ-
cus multilocularis (AER10554).
(TIF)
S3 Fig. Amino acid sequence comparison between Echinococcus AMPKγ and metazoan
orthologs. Consensus is indicated in the last line, total (uppercase letter), partial (lowercase let-
ter), conservative changes (asterisk), absence of consensus (dots) and gaps introduced to maxi-
mize the alignment (dashes). Eg-AMPKγ presents four cystathionine β-synthase (CBS) motifs:
CBS1 (underlined, 75–154), CBS2 (gray boxes, 53–74 and 155–209), CBS3 (broken-lined box,
230–300) and CBS4 (solid-lined boxes, 210–229 and 301–355) [75]. This protein conserves key
residues involved in binding to adenine nucleotides (R96, D116, H176, R177, K195, R196, T225, S251,
D270, H323, R324, S344, indicated by arrows) [76] and a pseudosubstrate sequence within the
CBS2 sequence (L164DAV167QMLL171EHKV175HR177LPILDPE, delimited by arrowheads)
[73]. GenBank accession numbers for the AMPKγ proteins are: Bm, Bombyx mori
Metformin Effects and AMPK Characterization in Echinococcus granulosus
PLOSONE | DOI:10.1371/journal.pone.0126009 May 12, 2015 18 / 23
(NP_001119720), Hs, Homo sapiens (P54619), Eg, Echinococcus granulosus (CDJ18193) and
Em, Echinococcus multilocularis (AER10556).
(TIF)
S4 Fig. Subcellular immunolocalization of total Eg-AMPKα from control E. granulosus
protoscoleces. Images of protoscoleces (i-l) and soma (a-d and m-p) and scolex (q-x) regions
visualized by fluorescence confocal microscopy stained with propidium iodide—red fluores-
cence, first column on the left-, revealed with AMPKα antibody conjugated with Alexa
488-green fluorescence, second column-, obtained by overlapping of the two fluorescence re-
actions (third column) and visualized by light transmitted microscopy (last column on the
right). The punctuate staining for Eg-AMPK-α expression was evenly detected in both nucle-
us (a-k, arrowheads) and cytoplasm (m-x, asterisk). Nuclear expression is observed in yellow/
orange, corresponding to the merged fluorescences (g and k, arrows). Bars indicate 5 μm (j-r),
10 μm (a-c) and 50 μm (d-i), tg: tegument; su: sucker; bo: cell body; rc: rostellar cone; cc:
calcareous corpuscle.
(TIF)
S5 Fig. Structural organization, sequence alignment and expression of LKB1. (A) Reverse
Transcription-PCR assay of Eg-lkb1 gene from total RNA of protoscoleces (PTS) and meta-
cestodes (MTC). Molecular size of amplicon is indicated with arrowhead. (B) Schematic re-
presentation of Homo sapiens LKB1 and of the only predicted LKB1 protein from the E.
granulosus genome. Identification of N-terminal regulatory domain (blue), kinase domain
(red) with activation loop (LAc, green), proline-rich C-terminal flanking tail (CFTL, orange)
and C-terminal regulatory domain (CDR, yellow). The proteins show conserved nuclear lo-
calization signal (indicated by a cross) and key residues involved in autophosphorylation (in-
dicated by arrows). (C) Multiple alignment of LKB1 orthologs. Consensus is indicated in the
last line, total (uppercase letter), partial (lowercase letter), conservative changes (asterisk),
absence of consensus (dots) and gaps introduced to maximize the alignment (dashes). Eg-
LKB1 presents a kinase domain (underlined, 94–526) with conserved residues in the LAc
(A384, D387, T409, P497, P498, P499, indicated by numeral) and key residues for catalysis and
substrate binding (D373, N320, D315, T395, H313, indicated by arrowheads), a CFTL (gray box,
491–527) and a CDR (broken-lined box, 530–622). Sequence also contains residues involved
in the structural integrity (R126, K130, R138, E150, D176, L303, I316, L321, A381, F382, L425, Y452,
L465, W512, indicated by arrows) [77]. GenBank accession numbers for the LKB1 proteins are:
Bm, Bombyx mori (NP_001119722) and Hs, Homo sapiens (Q15831). GeneDB predicted pro-
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